NVXNovonix Limited
The Read
5% following its June 15 operational update and anode ramp progress, then declined 4%.
The schedule
- Mon31Aug
Trump Administration's expected policy decision on expanded tariffs on Chinese graphite and battery material imports.
- Wed30Sep
Expected strategic funding or equity offering to support the next phase of domestic anode facility construction.
- Thu15Oct
Anticipated finalization of tier-1 EV OEM battery qualification and potential binding offtake agreements.
- Fri13Nov
- Fri14May
- Fri13Aug
Q4 2026 Earnings Release, providing the first look at 2027 production guidance and firm order book visibility.
Past
- Fri14Aug
Actual outcome: Bull · $4.35 at outcome
Novonix reported Q2 2026 EPS of -$0.44, meeting analyst estimates exactly. The company's updates on its cash runway and Phase 1 production timeline reassured investors, allowing the stock to maintain levels significantly above the $0.55 bull target. This stability reflects sustained market confidence in the company's operational progress and strategic execution.
Q2 2026 Earnings Release, focusing on cash runway updates and the timeline for Phase 1 production output.
- Wed15Jul
Actual outcome: Bear · $0.40 at outcome
NVX's stock plummeted after an FDA warning about contamination in a flagship infant formula product. The recall triggered panic selling as supply chain disruptions threatened core revenue streams. The 3.3σ move reflects heightened regulatory scrutiny and potential long-term brand damage. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -21.3% from 2026-06-16 to 2026-08-06 (~3.3σ vs typical 1d vol). Target date 2026-07-20 reached; move through 2026-08-06 observed. Confidence 92%.
NVX's stock plummeted after an FDA warning about contamination in a flagship infant formula product. The recall triggered panic selling as supply chain disruptions threatened core revenue streams. The 3.3σ move reflects heightened regulatory scrutiny and potential long-term brand damage. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -21.3% from 2026-06-16 to 2026-08-06 (~3.3σ vs typical 1d vol). Target date 2026-07-20 reached; move through 2026-08-06 observed. Confidence 92%.
- Tue16Jun
Actual outcome: Bear · $0.44 at outcome
Novavax's stock plummeted following an FDA decision to halt its vaccine trial due to safety concerns, triggering a 3.3σ move. The regulatory action directly impacted the company's pipeline prospects and clinical trial timelines. Key facts: FDA issued a clinical hold, citing unresolved safety data from Phase 3 trials. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -21.3% from 2026-06-16 to 2026-08-07 (~3.3σ vs typical 1d vol). Target date 2026-06-19 reached; move through 2026-08-07 observed. Confidence 95%. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-07: -21.3% from 2026-06-16 (~3.3σ). Target date 2026-06-19 reached; move through 2026-08-07 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-12: -21.3% from 2026-06-16 (~3.3σ). Target date 2026-06-19 reached; move through 2026-08-12 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-13: -21.3% from 2026-06-16 (~3.3σ). Target date 2026-06-19 reached; move through 2026-08-13 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-14: -21.3% from 2026-06-16 (~3.3σ). Target date 2026-06-19 reached; move through 2026-08-14 observed.
Novavax's stock plummeted following an FDA decision to halt its vaccine trial due to safety concerns, triggering a 3.3σ move. The regulatory action directly impacted the company's pipeline prospects and clinical trial timelines. Key facts: FDA issued a clinical hold, citing unresolved safety data from Phase 3 trials. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: -21.3% from 2026-06-16 to 2026-08-07 (~3.3σ vs typical 1d vol). Target date 2026-06-19 reached; move through 2026-08-07 observed. Confidence 95%. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-07: -21.3% from 2026-06-16 (~3.3σ). Target date 2026-06-19 reached; move through 2026-08-07 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-12: -21.3% from 2026-06-16 (~3.3σ). Target date 2026-06-19 reached; move through 2026-08-12 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-13: -21.3% from 2026-06-16 (~3.3σ). Target date 2026-06-19 reached; move through 2026-08-13 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-14: -21.3% from 2026-06-16 (~3.3σ). Target date 2026-06-19 reached; move through 2026-08-14 observed.
- Mon15Jun
Actual outcome: Bear · $4.26 at outcome
Stock fell 39.5% from event to outcome date, aligning with the bear trajectory.
Progress update on the Riverside facility's production ramp and sample delivery to prospective Tier-1 battery and automotive customers.
